Shares of NASDAQ ITRM opened at $12.00 on Tuesday. Iterum Therapeutics has a one year low of $11.23 and a one year high of $13.00.
In other news, CEO Corey N. Fishman acquired 3,000 shares of the firm’s stock in a transaction on Wednesday, May 30th. The shares were purchased at an average cost of $13.00 per share, with a total value of $39,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Patrick J. Heron acquired 456,099 shares of the firm’s stock in a transaction on Wednesday, May 30th. The stock was purchased at an average cost of $13.00 per share, for a total transaction of $5,929,287.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 965,099 shares of company stock worth $12,546,287.
There is no company description available for Iterum Therapeutics PLC.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.